Gonadectomy in Complete Androgen Insensitivity Syndrome: Why and When?

Area of Science:

• Reproductive Endocrinology
• Oncology
• Genetics

Background:

• Complete androgen insensitivity syndrome (CAIS) is associated with an elevated risk of malignant germ cell tumors in intra-abdominal gonads.
• Current screening methods for early detection of pre-malignant changes in CAIS gonads are unreliable.
• Prophylactic gonadectomy is recommended, but timing is debated due to low pre-pubertal risk and the desire for spontaneous puberty.

Purpose of the Study:

• To address the controversy surrounding gonadectomy timing in CAIS patients post-puberty.
• To investigate the challenges in assessing individual malignancy risk and hormone therapy in CAIS.
• To propose an alternative management strategy for women with CAIS who wish to retain their gonads.

Main Methods:

• Review of existing literature on CAIS, gonadal tumor risk, and management protocols.
• Analysis of endogenous hormone profiles and their influence on bone health and psychosocial well-being.
• Proposal of a biannual screening program for evaluation in a prospective multi-center trial.

Main Results:

• The absolute malignancy risk in individuals with CAIS is difficult to determine.
• Endogenous hormone profiles in CAIS have unique characteristics impacting various health aspects.
• Lack of robust studies supporting specific gonadectomy protocols or hormone therapy regimens.

Conclusions:

• A biannual screening program is proposed for women with CAIS who opt to retain their gonads.
• This program requires prospective multi-center trial evaluation to assess its efficacy and safety.
• Further research is needed to understand the full impact of endogenous hormone profiles in CAIS.